OncoQR ML (OQR) is a biotech startup that develops novel, adjustable cancer immunotherapies (ACIs) to treat oncologic diseases.
OncoQR – adjustable cancer immunotherapy
OQR’s ACIs are based on the unique, proprietary human specific S-TIR technology platform, which enables the patient’s immune system to generate a powerful immune response against tumor associated antigens. After subcutaneous or intramuscular application, the drug, through its warhead, docks specifically onto local CD32a (FcgammaRIIa) expressing cells such as monocytes and monocyte-derived dendritic cells (mDCs) as well as plasmacytoid dendritic cells (pDCs). In addition the ACI is recognized by immunogen specific B cells. OncoQR’s lead candidate is OQR100, targeting neutralization of G17 (“little gastrin”, a peptide growth factor/hormone produced by gastro-intestinal cancer cells) for treatment of pancreatic cancer. OQR100 is in co-development with TYG Oncology Ltd. under the name TYG100. TYG100 is the first adjustable cancer immunotherapy (ACI) derived from the S-TIR technology platform that was originally developed by S-TARget therapeutics GmbH for treatment of severe allergic diseases and out-licensed for oncology to OncoQR ML. Another lead candidate is OQR200, a new candidate against Her2/Neu to treat primarily breast cancer indications. In the next 2 years, several non disclosed new ACIs against clinically validated targets will be developed until at least in vivo proof of concept in Cynomolgus monkeys, after which the company will either seek for partners to bring these new ACIs into clinic or to out-license the products.
OncoQR was founded by two experienced, senior pharma professionals with top-level research & development as well as management backgrounds. Management Team is composed by Christof Langer, Geert Mudde and Jorge Sepulveda. Advisory board is composed by Jolanda de Vries, Reingard Grabherr and Gottfried Himmler.
More about OncoQR : www.oncoqr.com